Key result
Sarpogrelate treatment inhibited platelet aggregation dose-dependently in patients with ischemic stroke, with showing greater effect than or.
Why the study?
Does sarpogrelate dose-dependently inhibit platelet aggregation in patients with ischemic stroke?
RCT (n=47)
Double-blind
randomly assigned
Does sarpogrelate dose-dependently inhibit platelet aggregation in patients with ischemic stroke?
Sarpogrelate dose-dependently inhibits platelet aggregation in patients with ischemic stroke, with 100 mg TID showing superior efficacy to lower doses.
Answers are grounded in this paper and cite their sources.
100 mg TID yields superior platelet inhibition in ischemic stroke; confirms dose-dependency and informs dosing for outcome trials.
BACKGROUND AND PURPOSE: It is widely accepted that antiplatelet therapy is effective for secondary prevention of atherosclerotic vascular diseases. We performed a double-blind, controlled clinical-pharmacological study to investigate the antiplatelet efficacy of sarpogrelate, a selective 5-hydroxytryptamine (5-HT(2A)) receptor antagonist, in patients with ischemic stroke, using a new assessment system employing combinations of 5-HT and epinephrine as agonists. METHODS: Forty-seven patients with ischemic stroke were randomly assigned to three groups: 15 patients received 25 mg sarpogrelate (group L), 16 patients received 50 mg (group M), and 15 patients received 100 mg (group H) orally, three times daily for 7 days. The effect was expressed as maximum intensity of platelet aggregation on the last day of medication. Two combinations of agonists, 0.5 micromol/l 5-HT plus 3 micromol/l epinephrine, and 1 micromol/l 5-HT plus 3 micromol/l epinephrine, were used to induce platelet aggregation. RESULTS: With both combinations of agonists, sarpogrelate treatment inhibited platelet aggregation dose-dependently (p < 0.025, Jonckheere test). In multiple-group comparison, the effect in group H was greater than that in group L or M (p < 0.025, Wilcoxon rank-sum test). CONCLUSION: Sarpogrelate treatment inhibited platelet aggregation dose-dependently in patients with ischemic stroke, as judged by a new assessment system employing combinations of 5-HT and epinephrine as agonists.
No takes yet. Share an insight, caveat, or question.
Uchiyama et al. (2007) conducted an RCT in Ischemic stroke (n=47). Sarpogrelate vs. Lower doses (25 mg or 50 mg) was evaluated on Maximum intensity of platelet aggregation on the last day of medication (p=<0.025). Sarpogrelate treatment inhibited platelet aggregation dose-dependently in patients with ischemic stroke, with showing greater effect than or.
Synapse has enriched 10 related papers. Consider them for comparative context: